Stifel on X4 Pharmaceuticals (XFOR): 'today’s disclosure significantly de-risks the now enrolling P3 4WARD trial'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Brookline Capital Markets Reiterates Buy Rating on X4 Pharmaceuticals (XFOR)
June 27, 2024 4:00 PM EDTBrookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $4.32 price target on X4 Pharmaceuticals (NASDAQ: XFOR).
The analyst comments "The timing of interim phase II results for Mavorixafor for the treatment of chronic neutropenia (CN) is as anticipated, highly positive, and supportive of the recently initiated phase III study in this... More
X4 Pharmaceuticals (XFOR) Reports Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor
June 27, 2024 6:30 AM EDTX4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced positive new clinical data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of mavorixafor, an oral CXCR4 antagonist, in the treatment of people with chronic neutropenia (CN). An interim analysis of data from the ongoing six-month study showed that... More
